The DOI matches its Crossref record.
Prime-boost vectored malaria vaccines: Progress and prospects
Open accessAbstract
The difficulty of inducing protective immunity through antibodies against sporozoites led to efforts to assess vectored vaccines as a means of inducing protective T-cell immunity against the malaria liver-stage parasite. Although DNA vectored vaccines used alone were poorly immunogenic and not protective, high levels of parasite clearance in the liver has been achieved with viral vectored vaccines used in heterologous prime-boost regimes. Such vectored vaccination regimes represent one of only two approaches that have induced repeatable partial efficacy in human P. falciparum subunit vaccine trials. Interestingly, vectors expressing the TRAP antigen have been consistently been more immunogenic and protective than vectors expressing the circumsporozoite protein in human trials. However, sterile protection requires induction of very potent T-cell responses that are currently only achievable with heterologous prime-boost regimes. Recently, simian adenoviruses have been assessed as priming agents in Adenovirus-MVA regimes in both phase I and phase IIa trials in the UK, based on very promising pre-clinical results showing better immunogenicity and efficacy than previous prime-boost regimes. The same vectors are also being assessed clinically expressing blood-stage antigens, attempting to induce both protective antibodies and T cells as recently demonstrated in murine efficacy studies. These viral vectors now provide a major option for inclusion in a high efficacy multi-stage malaria vaccine that should achieve deployable levels of efficacy in endemic settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
Technologies for enhanced efficacy of DNA vaccines
Saade, F., & Petrovsky, N. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.188 · Cited by 309
Advances and challenges in malaria vaccine development
Crompton, P. D., Pierce, S. K., & Miller, L. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44423 · Cited by 269
Smallpox vaccines: targets of protective immunity
Moss, B. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00975.x · Cited by 259
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C., & Hill, A. V. S. (2017) · Scientific Reports · doi:10.1038/srep46621 · Cited by 253
Self-citationErsching, J., Vasconcelos, J. R., Ferreira, C. P., Caetano, B. C., Machado, A. V., Bruna–Romero, O., Baron, M. A., Ferreira, L. R. P., Cunha-Neto, E., Rock, K. L., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005593 · Cited by 18
Metadata
- Authors
- Hill, A. V. S., Reyes-Sandoval, A., O’Hara, G., Ewer, K., Lawrie, A., Goodman, A., Nicosia, A., Folgori, A., Colloca, S., Cortese, R., Gilbert, S. C., & Draper, S.
- Venue
- Human Vaccines
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 6
- Issue
- 1
- Pages
- 78-83
- ISSN
- 1554-8600 (ISSN-L)
- 1554-8619
- OpenAlex
- W2024411676
- Cited by
- 193
- References
- 0
- FWCI
- 30.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.